[Prophylaxis in hereditary angioedema with normal C1 inhibitor]

Area of Science:

• Genetics
• Immunology
• Pharmacology

Background:

• Hereditary angioedema (HAEA) is a rare genetic disorder causing swelling, often triggered by minor trauma.
• Types I and II HAEA can be managed with plasma-derived C1-inhibitor concentrate for short-term prophylaxis.
• Prophylaxis for HAEA with normal C1 inhibitor is not standardized, but C1 inhibitor concentrate may be beneficial.

Observation:

• A 69-year-old woman with hereditary angioedema with normal C1 inhibitor required multiple dental extractions.
• The patient received 1000 U of plasma-derived C1-inhibitor concentrate as prophylaxis one hour prior to the procedure under general anesthesia.
• Post-surgical care was provided in the ICU, and the patient experienced a favorable outcome.

Findings:

• Plasma-derived C1-inhibitor concentrate can be successfully used as prophylaxis in patients with hereditary angioedema with normal C1 inhibitor.
• This case demonstrates the efficacy of C1-inhibitor concentrate in preventing angioedema attacks during invasive procedures.

Implications:

• This successful prophylaxis highlights a potential treatment strategy for HAEA patients with normal C1 inhibitor.
• Further research may explore standardized prophylactic protocols using C1-inhibitor concentrate for specific HAEA subtypes and procedures.
• This approach could improve patient safety and reduce the risk of life-threatening swelling events in HAEA patients.